Mauris id enim id purus ornare tincidunt. Aenean vel consequat risus.Proin viverra nisi at nisl imperdiet auct...
Pioneering Targeted Cancer Treatments
Radioactive Biopolymer Technology Platform
At Blue Wave Therapeutics, we are at the forefront of developing a targeted radioactive biopolymer technology platform. This innovative platform uses targeted biopolymer nanoparticles to deliver radionuclides directly to tumor cells, providing highly targeted cancer treatments that minimize damage to healthy tissues and enhance therapeutic efficacy. Our approach represents a significant advancement in the field of nuclear medicine and oncology.
Pipeline
Advancing Innovative Therapies
Blue Wave Therapeutics is committed to the development of groundbreaking therapies for the treatment of solid tumors. Our pipeline reflects our rigorous scientific approach and dedication to bringing new therapeutic solutions to patients with critical unmet needs. Besides our first product candidate ARAspheres, Blue Wave is exploring two further candidates with undisclosed target and indication.
Glioblastoma
Targeting Aggressive Brain Tumors
Glioblastoma is one of the most aggressive and difficult-to-treat brain tumors. Blue Wave Therapeutics is developing ARAspheres to address this critical unmet medical need. Our technology targets glioblastoma cells with precision, delivering alpha radiation directly to the tumor and sparing healthy brain tissue. Our goal is to significantly improve survival rates and quality of life for patients with glioblastoma.
ARAspheres
Innovative Nanoparticle Therapy
ARAspheres represent the first product candidate from Blue Wave Therapeutics’ targeted biopolymer platform: they are designed to specifically carry radionuclides to tumor cells. In fact, these nanoparticles use a targeting peptide, RGD, to bind specifically to tumor cell receptors, ensuring precise delivery of alpha radiation. This innovative approach holds great promise for treating various solid tumors, starting with glioblastoma.
Fluorescent calcium alginate microparticles
Calcium alginate microparticles labelled with fluoresceinamine
Visible light photomicrograph (10x)
Visible light photomicrograph (10x)
Fluorescent excitation 488 nm (same field of view)
Administration Modality
01
Patient with glioblastoma
The tumor is removed by surgery
02
After surgery
After surgery, ARAspheres are injected into the surgical cavity and diffuse into the brain
03
Residual tumor cells
Residual tumor cells are irradiated continuously, until radionuclide decays
03
Cavity Tissue Infusion
Upon biopolymer degradation, the brain tissue slowly fills the cavity
Key R&D Milestones
Publications
Sharing Our Scientific Discoveries
At Blue Wave Therapeutics, we believe in the importance of scientific transparency and collaboration. Our publications section will feature research papers, articles, and other relevant publications.
Mauris id enim id purus ornare tincidunt. Aenean vel consequat risus.Proin viverra nisi at nisl imperdiet auct...
Mauris id enim id purus ornare tincidunt. Aenean vel consequat risus.Proin viverra nisi at nisl imperdiet auct...
Ready To Help
Get in touch with us